RxDoctor Payments Data

Paul Berenbaum, MD

Gastroenterology · Jenkintown, PANPI 1265595904

Payments from drug & device makers

$24,161in general payments, 2019–2025

Across 351 payments — averaging $68.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$13K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$8K
  • Takeda Pharmaceuticals U.S.A., Inc.$524
  • Johnson & Johnson$424
  • Intra-sana Laboratories$416
  • QOL Medical, LLC$268
  • plus $1K from 17 others

What the payments were for

  • Consulting fees$140%
  • Speaking & faculty fees$16,65069%
  • Travel & lodging$1,4016%
  • Food & beverage$6,04325%
  • Education$540%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,161 in reported general payments places this provider in the 80th percentile of 935 gastroenterology providers in Pennsylvania.

See all gastroenterology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$20,051
Medicare patients
48
Services billed
121

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide112$93,031
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate11$52,407
CreonLipase/Protease/Amylase15$34,010
Ursodiol43$30,406
Mesalamine70$26,919
VemlidyTenofovir Alafenamide11$20,651
Dexlansoprazole DrDexlansoprazole41$19,739
DexilantDexlansoprazole14$8,190
Lansoprazole160$5,729
Famotidine199$2,287
Omeprazole34$495
Metoclopramide Hcl51$451
Ezetimibe21$178
Rosuvastatin Calcium22$154
Escitalopram Oxalate17$114

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$12,845$127,041127 claims
GileadVemlidy$225$20,65111 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$524$8,19014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 935 gastroenterology providers in Pennsylvania.

Other gastroenterology in Jenkintown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →